The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

4/17/25 8:34:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XOMA

Date	Price Target	Rating	Analyst
4/17/2025	$35.00	Buy	The Benchmark Company
4/29/2024	$40.00	Outperform	Leerink Partners
10/8/2021	$56.00 → $69.00	Buy	HC Wainwright & Co.
9/9/2021	$60.00 → $56.00	Buy	Aegis Capital
9/7/2021	$22.00	Outperform → Neutral	Wedbush
9/7/2021	$22.00	Neutral → Underperform	Wedbush
6/29/2021	$60.00	Buy	Aegis Capital